MANVF yields 1333.33% · JNJ yields 2.13%● Live data
📍 MANVF pulled ahead of the other in Year 1
Combined, MANVF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MANVF + JNJ for your $10,000?
Manning Ventures Inc. engages in the sourcing and exploration of mineral properties in Canada. It primarily explores for gold, silver, lead, iron ore, zinc, cobalt, uranium, rare earth, and copper deposits. The company holds interest in the Flint Lake gold project, which includes 4 separate unpatented claims covering an area of approximately 1,712 hectares located in Kenora town, northwestern Ontario. It also holds interest in the Lac Simone property, which consists of 63 mineral claims covering an area of approximately 3,287.4 hectares; and the Hope Lake property which includes 68 mineral claims covering an area of approximately 3,584.1 hectares. In addition, the has an option to acquire a 100% interest in the Broken Lake, Heart Lake, and Hydro properties that consist of 180 mineral claims covering an area of 9,501 hectares located in the Province of Quebec; and the Bounty lithium project comprises 144 mineral claims totaling 7,544 hectares. Further, it holds interest in Butterfly Pond property covering an area of 425 hectares, Mount Hogan property which covers an area of 250 hectares, Red Indian Lake property covering an area of 9,300 hectares, and Little Sheep Brook property covering an area of 700 hectares located in Newfoundland, Canada. Manning Ventures Inc. was incorporated in 2018 and is based in Vancouver, Canada.
Full MANVF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.